Showing 631-640 of 1351 results for "".
- Amgen/Kyowa Kirin's Anti-OX40 Shows Efficacy in Phase 2 for ADhttps://practicaldermatology.com/news/amgenkyowa-kirins-anti-ox40-shows-efficacy-in-phase-2-for-ad/2460943/Positive data from a Phase 2 study of AMG 451/KHK4083, presented at the European Academy of Dermatology and Venereology 30th Virtual Congress, show that the potential first-in-class anti-OX40 fully human monoclonal antibody in development for the treatment of moderate-to-severe atopic d
- First Patient Dosed in Kinnate's Phase 1 trial of KIN-2787 in Patients with BRAF Mutation-Positive Solid Tumorshttps://practicaldermatology.com/news/first-patient-dosed-in-kinnates-phase-1-trial-of-kin-2787-in-patients-with-braf-mutation-positive-solid-tumors/2460894/The first patient has commenced treatment in Kinnate Biopharma Inc.’s Phase 1 KN-8701 trial of its lead RAF product candidate, KIN-2787, a pan-RAF inhibitor being developed for the treatment of patients with melanoma, lung cancer, and other solid tumors. While three kina
- Parents Magazine Announces Winners of Best Skin Care for Kids 2021https://practicaldermatology.com/news/parents-magazine-announces-winners-of-best-skin-care-for-kids-2021/2460823/Meredith Corporation's Parents magazine released this year's Best Skin Care for Kids. Parents experts thoroughly tested nearly 300 formulas of parent recommendations, brand best-sellers, and new releases for skin and hair with 55 families. A total of 30 products that are a
- HydraFacial and Vesper Healthcare Announce Closing of Business Combination, Combined Company Now Known as The Beauty Health Companyhttps://practicaldermatology.com/news/hydrafacial-and-vesper-healthcare-announce-close-business-combination-combined-company-now-known-as-the-beauty-health-company/2460800/It's officially official: Vesper Healthcare and The HydraFacial Company closed their previously announced business combination. The combined company will be known as The Beauty Health Company. The business combination was approved by Vesper Healthcare’s st
- Cetaphil Launches Mineral Sunscreen Line, Kicks Off Educational Campaignhttps://practicaldermatology.com/news/cetaphil-launches-mineral-sunscreen-line-kicks-off-educational-campaign/2460794/Cetaphil is kicking off a campaign to help educate the public about sun safety to help prevent skin cancer. Throughout the month of May, Cetaphil and its leading dermatologist ambassadors will be dedicated to maximizing awareness of the symptoms, ca
- Kintor Doses First Group of Acne Patients in Phase I/II Clinical Trial of Pyrilutamidehttps://practicaldermatology.com/news/kintor-doses-first-group-of-acne-patients-in-phase-iii-clinical-trial-of-pyrilutamide/2460752/Kintor Pharmaceutical Limited successfully dosed the first group of patients in the clinical trial of Pyrilutamide as a treatment for the acne vulgaris. The Phase I/II clinical trial in China is a randomized, double-blind, placebo-controlled clinical study to evalu
- Kenneth J. Tomecki, MD, FAAD is New President of the AADhttps://practicaldermatology.com/news/kenneth-j-tomecki-md-faad-is-new-president-of-the-aad/2460723/Kenneth J. Tomecki, MD, FAAD is now president of the American Academy of Dermatology (AAD). During his one-year term, Dr. Tomecki will lead the world’s largest dermatologic society, representing more than 20,000 physicians specializing
- Klisyri Launches for Treatment of AKshttps://practicaldermatology.com/news/klisyri-launches-for-treatment-of-aks/2460691/Klisyri® (tirbanibulin) ointment 1% is now available from Almirall, SA for the topical treatment of actinic keratosis (AK) of the face and scalp. Klisyri is supplied in boxes of 5 single-use sachets and is applied to the treatment area once daily for five days. "Klisy
- Almirall’s Klisyri Performs Well in Phase III AK Trialshttps://practicaldermatology.com/news/almiralls-klisyri-performs-well-in-phase-iii-ak-trials/2460687/Almirall’s Klisyri (tirbanibulin) ointment demonstrated complete clearance of actinic keratosis (AK) lesions at day 57 in treated face or scalp areas in a significantly higher number of patients than vehicle, according to Phase III trials. What’s more, Klisyri is safe with n
- Katie Cheng Is Cynosure's New CMOhttps://practicaldermatology.com/news/katie-cheng-is-cynosures-new-cmo/2460646/Katie Cheng is Cynosure’s new Chief Marketing Officer. "Katie's proven track record of consumer and professional marketing strategy and execution is one of the many reasons we are eager to have Katie join our team," says Cynosure CEO Todd Tillemans, i